Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $260.00 at Evercore ISI

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target upped by investment analysts at Evercore ISI from $210.00 to $260.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Evercore ISI’s price target would suggest a potential upside of 6.05% from the stock’s previous close.

Several other research firms also recently issued reports on ALNY. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an “equal weight” rating in a report on Tuesday. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $283.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Eight research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $242.52.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $245.17 on Tuesday. The firm has a market cap of $31.01 billion, a PE ratio of -91.48 and a beta of 0.30. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $249.33. The firm’s fifty day moving average is $155.86 and its 200 day moving average is $163.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.40) earnings per share. Research analysts predict that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CMO Pushkal Garg sold 2,103 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the transaction, the chief marketing officer now owns 15,609 shares of the company’s stock, valued at approximately $3,605,522.91. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,357 shares of company stock valued at $13,436,711. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its stake in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the period. Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $30,000. Quent Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $38,000. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.